MSB
Mesoblast Ltd
$2.04
▼ -5.56%
Market cap
$2.65B
Turnover
$6,784,310
Last price
$2.04
Day change
-5.56%
Announcements
13
Range, past year
Open 2.420 · Low 1.527 · Now 2.040 · High 3.310
Open MSB in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
MSB momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-09-28.
Momentum quality
24/100
Wyckoff phase
Downtrend1d
Trend stage
Breakdown
1 Day
-5.6%
1 Week
-4.2%
1 Month
-17.1%
1 Year
-15.0%
RSI
37
Avg daily range
4.5%
Mesoblast Ltd scores 24 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.
On the Wyckoff cycle it sits in Downtrend, where it has been for 1 trading day. The weekly timeframe reads Downtrend, which agrees with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
Points to watch
- 60d drawdown -26.7%
- Risk rating: Very High
- Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsMSB announcements
Recent price-sensitive releases.
- 2026-09-24 FDA Approves New Potency Assay for Commercial Ryoncil Progress Report
- 2026-08-27 MSB Annual Financial Results and Operational Update Web Cast | Preliminary Final Report
- 2026-08-27 Annual Financial Results Presentation Company Presentation | Preliminary Final Report
- 2026-08-27 Preliminary Final Report including Appendix 4E Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement
- 2026-08-17 Major Milestone Treatment Completed in P3 Trial for CLBP Progress Report
- 2026-07-30 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-07-14 Pivotal Phase 3 Trial in CLBP Achieves 300 Treated Patients
More Health Care stocks
Most traded in the same sector.